Evidence map›Paper›PMID 42386766›Full record

ArticleNPJ breast cancer2026

Identifying the window of aggressive postpartum breast cancer based on the 21-gene Oncotype DX® test in women with HR+, HER2-negative breast cancer.

Shiliang Zhang, Katelyn J Queen, Niharika Duggirala, Eric Yang, Marla Lipsyc-Sharf, Jennifer Racz, John Bennett, Kaden Hong, Yashila Suresh, Charlotte Hamilton and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shiliang Zhang *Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. shiliangzhang@mednet.ucla.edu.
Katelyn J Queen *Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Niharika DuggiralaDavid Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Eric YangCollege of Letters and Science, University of California, Los Angeles, Los Angeles, CA, USA.
Marla Lipsyc-SharfDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Jennifer RaczMedical Affairs, Abbott, Redwood City, CA, USA.
John BennettClinical Biostatistics, Abbott, Redwood City, CA, USA.
Kaden HongCollege of Letters and Science, University of California, Los Angeles, Los Angeles, CA, USA.
Yashila SureshCollege of Letters and Science, University of California, Los Angeles, Los Angeles, CA, USA.
Charlotte HamiltonCollege of Letters and Science, University of California, Los Angeles, Los Angeles, CA, USA.
Meghana PittaCollege of Letters and Science, University of California, Los Angeles, Los Angeles, CA, USA.
Nicole ChienCollege of Letters and Science, University of California, Los Angeles, Los Angeles, CA, USA.
Emily LaCollege of Letters and Science, University of California, Los Angeles, Los Angeles, CA, USA.
Christy A RussellMedical Affairs, Abbott, Redwood City, CA, USA.
Aditya BardiaDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Nimmi S KapoorDepartment of Surgery, University of California, Los Angeles, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Postpartum breast cancer (PPBC) is associated with worse outcomes in young women with breast cancer and demonstrates distinct transcriptomic features, yet a temporal definition based on gene expression has not been established. We conducted a single-institution retrospective cohort study to evaluate the impact of postpartum status on the 21-gene Oncotype DX Recurrence Score® (RS) in hormone receptor-positive, HER2-negative young women with breast cancer. Among 385 patients, 153 were nulliparous, 62 were more than 10 years postpartum, and 170 were within 10 years postpartum. Diagnosis within one year of childbirth was associated with a 13.2-point higher RS compared with nulliparous patients (p < 0.001). Defining PPBC as within 3 years postpartum was associated with increased odds of RS category shift (OR 2.83, p = 0.001). In the context of contemporary adjuvant treatment, with patients diagnosed within three years postpartum more likely to receive chemotherapy, ovarian function suppression, and CDK4/6 inhibitors, differences in IDFS associated with time since last childbirth did not result in significantly worse IDFS within the follow-up period (89.0% in patients with PPBC up to 3 years vs. 93.7% in all other patients p = 0.39). These findings indicate that tumors diagnosed within the first year postpartum have significantly elevated RS, and that the period of most aggressive PPBC, as reflected by gene expression profiles, may arise in the more recently postpartum period, in the first 0-3 years postpartum.

Identifiers

PMID42386766
PMCPMC13686956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.